Treatment Of Children With Short Stature At An Age Of 3-7 Years Who Were Born Small For Gestational Age

• Status: Completed
• Trial end date: 2005-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective is to evaluate, if Genotonorm (Genotropin) increases linear growth in short children born SGA. Safety of the drug is a main objective as well. The growth promoting effect of two different dosages is compared. The effect of long-term treatment on final height is evaluated (according to several amendments)

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Birth length below -2 SD

• Height at start below - 2 Sd

Exclusion Criteria:

• Any endocrine or chronic disease

• Any known syndrome with short stature